Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancer

Clinical Breast Cancer

Volumn 4, Issue 4, 2003, Pages 292-294

  Ramaswamy, Bhuvaneswari ^a   Shapiro, Charles L ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Monoclonal antibody; Vascular endothelial growth factor

Indexed keywords

ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CAPECITABINE; DOCETAXEL; PACLITAXEL;

ADVANCED CANCER; ARTHRALGIA; ARTICLE; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; CHILL; CLINICAL TRIAL; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DYSPNEA; EDEMA; FEMALE; FEVER; FLUID RETENTION; HEADACHE; HUMAN; HYPERTENSION; INFECTION; INTESTINE OBSTRUCTION; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; NEPHROTIC SYNDROME; NEUROPATHY; NEUTROPENIA; PROTEINURIA; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; THROMBOEMBOLISM; WEIGHT GAIN;

EID: 0347532594     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2003.n.035     Document Type: Article

References (26)

1. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and thieir inhibitors. Nat Med 1999; 5:1359-1364.
2. Isner J, Pieczek A, Schainfield R, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF 165 in patients with ischemic limb. Lancet 1996; 348:370-374.
3. Ferrera N, Houck K, Jakeman L, et al. Molecular and biological properties of the vascular endothelial cell growth factor family of proteins. Endocrinol Rev 1992; 13:18-32.
4. Ferrara N, David-Smyth T. The biology of vascular endothelial growth factor. Endocrinol Rev 1997; 18:1-22.
5. Investigator Brochure for Recombinant Humanized Monoclonal Anti-VEGF Antibody (Bevacizumab). South San Francisco, CA: Genentech, Inc.
6. Borgstrom P, Gold DP, Hillan KJ, and Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999; 19:4203-4214.
7. Kim L, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362:841-844.
8. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19:843-850.
9. Margolin K, Gordon MS, Hologram E, et al. Phase trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacological and long-term safety data. J Clin Oncol 2001; 19:851-856.
10. Weidner N, Folkman J. Tumor vascularity as a prognostic factor in cancer. In: De Vita VT Jr, Hellman S, Rosenberg S, eds. Cancer: principles and practice of oncology, 5th ed.; PPO Updates (11-7). Cedar Knolls, NJ: Lippincott-Raven, 1997:1-24.
11. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1999; 84:1875-1887.
12. Guidi AJ, Berry DA, Broadwater G, et al. Association of angiogenesis in lymph node metastasis with outcome of breast cancer. J Natl Cancer Inst 2000; 92:486-492.
13. Fox SB. Tumor angiogenesis and prognosis. Histopathology 1997; 30:294-301.
14. Sledge G, Miller K, Novotny W, et al. A phase II trial of single agent rhuMAb VEGF in patients with relapsed metastatic breast cancer. Proc Am Soc Clin Oncol 2000; 19:3a (Abstract #5C)
15. Miller KD, Rugo HS, Cobleigh MA, et al. Phase III trial of capecitabline (Xeloda®) plus Bevacizumab (Avastin™) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breat Cancer Res Treat 2002; 76:S37 (Abstract #36).
16. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patiens with metastatic breast cancer. J Clin Oncol 1999; 17:2341-2348.
17. Valero V. Docetaxel as single-agent therapy in metastatic breast cancer clinical efficacy. Semin Oncol 1997; 24(4 suppl 13):S13-S11, S13-S18.
18. Valero V, Holmes FA, Walters RS, et al. Phase II study of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13:2886-2894.
19. Ravdin PM, Burrsi HA III, Cool G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13:2879-2885.
20. Hainsworth J, Burris H, Erland J, et al. Phase I trial of docetaxel administered bi-weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998; 16:2164-2168.
21. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18:1212-1219.
22. Kakeji Y, Maehara Y, Ikebe M, et al. Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-beta levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma. Int J Radiat Oncol Biol Phys 1997; 37:1115-1123.
23. Sweeney C, Sledge GJ. Chemotherapy agents as antiangiogenic therapy. Cancer Conference Highlighs 1999; 3:2-4.
24. Sweeney C, Miller KD, Sissons S, et al. The antiangiogenic property of docetaxel is synergistic with recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001; 61:3369-3373.
25. Byrne GJ, Ghellal A, Iddon J, et al. Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J Nat Cancer Inst 2000; 92:1329-1336.
26. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.